Vincent DEQUENNE

About Vincent DEQUENNE

Vincent Dequenne is the Chief Operating Officer of Valneva SE, the specialty vaccine company focused on preventing infectious diseases. He joined Valneva in July 2021, initially as Senior Vice President Operations, before taking on broader operational leadership responsibilities within the executive team. His remit is central to the company’s industrial execution, manufacturing organization, and operational delivery of Valneva’s strategic priorities. Prior to joining Valneva, Dequenne built more than 20 years of experience in the biopharmaceutical industry, holding leadership roles at Eurogentec, Eli Lilly, GSK Vaccines, and Pierre Fabre. Across these positions, he developed deep expertise in vaccine and drug manufacturing, CDMO operations, engineering, and validation activities. Trained as an engineer, with an MSc in Mechanical Engineering, Dequenne brings a strong technical and hands-on approach to industrial leadership. At Valneva, his responsibilities are closely linked to critical value drivers for a listed life sciences company: securing manufacturing capacity, scaling operations, improving process reliability, managing quality, and ensuring operational resilience. In a vaccine business, where production quality, regulatory discipline, and supply-chain robustness are essential, his background is particularly relevant. His career reflects a profile that combines technical depth with operational leadership in highly regulated environments. At Valneva, he contributes to building and maintaining an industrial platform capable of supporting the company’s vaccine portfolio and international growth ambitions. His experience across large pharmaceutical and vaccine organizations gives him a solid perspective on manufacturing excellence, process validation, and industrial transformation. As a result, Vincent Dequenne stands out as an executive whose expertise is rooted in execution, quality, and operational rigor. For a company like Valneva, those capabilities are fundamental to translating scientific innovation into reliable, scalable vaccine production and long-term value creation.